GP9

Across TCGA pan-cancer cohorts, GP9 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GP9 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher GP9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GP9 expression acts as an unfavorable survival marker.

SCLC are the cancer types where GP9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

GP9–SCLC (OS)

Open the SCLC breakdown →